Authors: K Höfner M Burkart G Jacob U Jonas
Publish Date: 2009/12/10
Volume: 28, Issue: 3, Pages: 353-357
Abstract
To investigate the symptomatic and quality of life QoL response to treatment with tolterodine extended release ER in subgroups of male patients with Overactive Bladder Syndrome OAB and LUTS suggestive of nonobstructive benign prostatic hyperplasia BPH according to age symptom severity diabetes mellitus status and concomitant treatment for LUTSPatients treated with tolterodine ER 4 mg/day for OAB symptoms alone or added to unsuccessful alphablocker treatment of ≥6 weeks duration and presumed nonobstructive BPH Q max ≥ 15 ml/s were observed for 12 weeks in a noninterventional study Patients completed the International Prostate Symptom Score IPSS and Overactive Bladder Questionnaire OABq at baseline and after 12 weeks524 of 741 patients were aged ≤65 years 4 64 and 32 had mild moderate and severe symptoms respectively according to IPSS 14 had diabetes mellitus and in 42 tolterodine was added to alpha blockers In the various subgroups mean IPSS total scores improved by 28–111 points IPSS QoL scores by 18–24 points and all OABq subscores by more than 14 points Only IPSS and OABq baseline scores had a relevant impact on changes during treatment benefits were greatest in patients with more severe symptoms and botherIn men with symptoms of OAB and LUTS suggestive of nonobstructive BPH of all IPSS severity classes aged ≤65 years or above with or without concomitant diabetes or alphablockers symptoms and QoL improved markedly during treatment with tolterodine ER
Keywords: